Actinogen is a neurotherapeutics developer realizing a revolutionary therapy so neurology patients and their families can live their best lives

ACW CMO presents Xanamem pTau poster at ADPD25 conference

ACW Chief Medical Officer, Dr Dana Hilt MD is presenting an academic poster at the 19th International Conference on Alzheimer’s & Parkinson’s Diseases and Related Neurological Disorders (AD/PD™25)  in Vienna, Austria.

The poster details the promising benefits of Xanamem® treatment over 12 weeks in patients with elevated blood pTau181. It also reports that higher levels of blood pTau181 can identify patients with Alzheimer’s disease who have more rapid clinical progression.

Actinogen conducts Type C meeting with FDA regarding depression

Actinogen announces the successful conduct of its scheduled Type C meeting on major depressive disorder (MDD) with the US Food & Drug Administration (FDA).

In a collegial meeting, Actinogen and the FDA reached a common understanding of the additional clinical trials, ancillary clinical pharmacology trials and nonclinical studies required to apply for marketing approval of Xanamem for MDD in the future.

CEO presentation to ASX SMIDCaps conference

ACW CEO, Dr Steven Gourlay presented at the ASX small & mid-caps conference in Sydney.

Dr Gourlay’s presentation (attached to the announcement) outlines the attractive therapeutic profile of ACW’s novel small molecule drug Xanamem and provides an update as the company approaches critical milestones in its phase 2b/3 Alzheimer’s trial.

ACW releases 2025 interim financial results and reports

Actinogen has released its 2025 interim financial results for the six months ended 31 December 2024.

The company is advancing quickly to late stage clinical development as outlined in the results announcement.

To see the Appendix 4D and Interim financial report, click the link immediately below.

View Interim report & Appendix 4D

Peer-reviewed clinical pharmacology manuscript published

ACW has announced the publication of its most recent peer-reviewed journal article in Clinical Pharmacology in Drug Development, the journal associated with the American College of Clinical Pharmacology.

The review confirms the utility of the 10 mg daily dose of Xanamem being used in current clinical trials.

View journal article